Efficacy of AI and Machine Learning in Diagnosing Heart Valve Disease: A Five - Year Review

Vansh Marwaha

Medical Student at Avalon University School of Medicine, Willemstad, Curacao
Email: vanshmarwaha18[at]gmail.com

Abstract: **Background:** Valvular heart diseases pose significant diagnostic challenges, prompting the exploration of artificial intelligence (AI) and machine learning (ML) to improve the accuracy and patient outcomes. This systematic review examines the recent five - year advancements in AI/ML applications for valvular heart disease diagnostics and their impact compared to traditional methods. **Methods:** A comprehensive search was conducted in PubMed and Google Scholar from October 2018 to October 2023 which yielded 326 articles. After title and abstract screening, 73 articles underwent full - text review, resulting in the exclusion of 70 articles due to reasons such as other heart related/diverse diseases, absence of AI/ML use, and lack of clinical validation. Finally, 03 articles met the rigorous inclusion criteria and were included in this systematic review. **Results:** The selected studies applied artificial intelligence (AI) and machine learning (ML) techniques in valvular heart disease diagnosis. These studies revealed significant insights, associating specific biomarkers with adverse outcomes in aortic stenosis, also developing ECG - based models effectively identifying high - risk patients with multiple heart conditions, and introducing precision algorithms that accurately predicted severe valvular stenosis, potentially reducing missed diagnoses and aiding clinical prioritization. **Conclusions:** Despite promising advancements in AI - driven valvular heart disease diagnostics, challenges include limited validation, echocardiographic accuracy issues, and diversity gaps. Future efforts must focus on refining algorithms, integrating diverse data, broader validation, and addressing demographic diversity to ensure accurate and clinically relevant diagnostic outcomes. Additionally, this systematic review evaluates the advancements in AI and ML for diagnosing valvular heart disease over the past five years. It analyzes three key studies, focusing on improved diagnostic accuracy, methodological approaches, and the impact on patient outcomes compared to traditional methods. The review highlights significant findings, underscores potential challenges, and suggests future directions for research in this domain.

**Keywords:** Artificial Intelligence (AI), Machine Learning (ML)

1. **Background/ Introduction**

Heart valve disease, encompassing valvular heart disease or valvular disease, remains a significant concern in cardiology due to its prevalence and potential clinical implications. Over the past few years, the integration of artificial intelligence and machine learning into medical diagnostics has opened up new avenues for improving the accuracy and efficiency of diagnosing heart valve diseases, thereby influencing patient outcomes. This systematic review aims to investigate the recent advancements in the field by assessing whether the use of artificial intelligence or machine learning for diagnosis has indeed led to enhanced diagnostic accuracy and positively impacted patient outcomes in comparison to traditional diagnostic methods.

As the prevalence of valvular heart disease continues to rise, there is a growing need for accurate and timely diagnosis to guide effective treatment decisions. Machine learning - based diagnostic models for valvular heart disease have been explored in recent studies (1), offering the promise of more precise diagnostic tools. Furthermore, the utilization of artificial intelligence in cardiac imaging for valvular heart disease has attracted significant attention (2), with the potential to revolutionize the non - invasive evaluation of these conditions.

AI, a broad and evolving field, offers the capability for machines to perform tasks that traditionally require human intelligence, including pattern recognition, planning, language understanding, and problem - solving (3). Machine learning (ML), a subset of AI, enables machines to learn from data and progressively identify patterns without being explicitly programmed (3). In healthcare, AI and ML can leverage data collected from electronic health records, medical imaging, and other sources to enhance diagnostic accuracy, prediction, and treatment selection, contributing to the broader concept of precision medicine (3).

AI and ML in cardiology have the potential to revolutionize the way heart valve diseases are diagnosed, assessed, and managed. These technologies offer clinicians more accurate and standardized image interpretation, improved diagnosis, risk prediction, and guidance on treatment options tailored to individual patients (4). Moreover, they can optimize workflow, reduce medical errors, and ultimately lead to better patient outcomes within health systems (4). Patients themselves can also benefit by processing their health data and accessing opportunities for primary and secondary cardiovascular health prevention (4).

Historically, computer algorithms and early AI information systems in clinical decision - making, including those focused on cardiovascular medicine, have been explored (7). These early systems used mathematical models to aid in the diagnosis and interpretation of laboratory results (7). As technology has advanced, AI and ML offer the potential to overcome these limitations and unlock the power of big data. Recent studies have demonstrated the application of AI and ML in identifying biomarkers, assessing pathophysiology, and improving prognosis in cardiovascular diseases, including heart valve diseases (6). AI - driven predictive models are capable of stratifying patients based on risk factors, offering tailored recommendations, and facilitating early detection (6).

Volume 12 Issue 11, November 2023
www.ijsr.net
Licensed Under Creative Commons Attribution CC BY

Paper ID: SR231122033950
DOI: https://dx.doi.org/10.21275/SR231122033950
Diagnostic accuracy is a critical factor in improving patient care, and the systematic review will consider the findings of a study on the diagnostic accuracy of artificial intelligence in evaluating valvular heart disease (7). The review will also dive into comparative studies that assess the performance of machine learning algorithms for diagnosing valvular heart disease (8). By analyzing these studies, we aim to provide a comprehensive overview of the current state of research in this field and shed light on the potential benefits and challenges associated with the adoption of artificial intelligence and machine learning in the diagnosis of heart valve disease.

2. Methods

2.1 Study Design

This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure the transparent and comprehensive reporting of the study selection and inclusion process (Figure 01)

Information Sources
We conducted an extensive literature search using two primary databases: PubMed and Google Scholar. Our search strategy involved combination of headings (MeSH) terms and keywords to ensure a comprehensive coverage of relevant articles. The search was restricted to articles published from October 1, 2018, to October 1, 2023.

For the Google Scholar search, we applied specific filters to enhance the search results, including limiting the publication date range to 2018 - 2023 and focusing on review articles exclusively.

Search Strategy
The following keywords and MeSH terms were used in the search strategy:

- ("Heart Valve Disease" OR "Valvular Heart Disease" OR "Valvular Disease" OR "Cardiac Valve Disorders") AND
- ("Artificial Intelligence" OR "Machine Learning" OR "Machine Intelligence" OR "Computational Intelligence") AND
- ("Diagnosis" OR "Diagnostic" OR "Diagnose" OR "Medical Diagnosis" OR "Diagnostic Methods" OR "Clinical Diagnosis") AND
- ("Patient Outcomes" OR "Health Outcomes" OR "Clinical Outcomes" OR "Patient Health")

Study Inclusion Criteria
The inclusion and exclusion criteria for article selection were defined according to the PICOT (Population, Intervention, Comparison, Outcome, and Timeframe) format:

Population: Studies involving patients with heart valve disease, as well as those who have developed complications as a result of the disease.
Intervention: Studies that utilize artificial intelligence (AI) or machine learning (ML) for the diagnosis of heart valve disease.

Comparison: Studies that include a comparison with old traditional methods of diagnostics.

Outcome: Studies that report on diagnostic accuracy measures and/or patient outcomes (e.g., treatment decisions, prognosis, patient well-being).

Timeframe: Studies published within the past five years (from October 1, 2018, to October 1, 2023).

Study Selection Process
A total of 326 articles were found which includes articles from both the databases.

Articles were initially screened based on their titles and abstracts to assess their relevance to the inclusion criteria. A total of 73 articles were selected for full-text review after this initial screening of 326 articles.

During the full-text review, 70 articles were excluded based on predefined exclusion criteria, which included reasons such as:
- Diseases other than heart valve disorders.
- The absence of AI or ML use for diagnostic purposes.
- Lack of comparison with traditional diagnostic methods.
- Absence of Real-Time Application or Clinical Validation: Articles that were primarily review-based and did not present empirical studies involving machine learning applied to a sample population for diagnostic purposes.

The final selection resulted in 3 articles that met all inclusion criteria and were included in the systematic review. The selection of 3 articles ensured that there was deep focused analysis and clear synthesis.

Analysis of Methodological Quality and Data Retrieval
Data extraction from the studies selected after full-text screening aimed to identify relevant patient conditions, specifically heart valve diseases and any comorbidity associated with heart valve diseases. The quality assessment of these selected studies was conducted according to established quality appraisal guidelines, and any discrepancies were resolved through careful consideration.

The methodological quality of each selected study was independently evaluated. The following quality items were utilized for the assessment:
- Diagnostic Criteria for Valvular Heart Disease: The assessment focused on whether the selected studies clearly defined the diagnostic criteria for valvular heart disease, ensuring that the disease was accurately and consistently identified.
- Description of Study Sample: Examination of whether the studies provided a comprehensive description of the study sample, including whether patients were experiencing symptoms that led to diagnostic testing or if valve testing was conducted as part of routine screening/Echocardiographic reports.

- Utilization of Diagnostic Algorithms: Assessment of whether the studies incorporated diagnostic algorithms during imaging procedures to enhance the prognosis of heart valve diseases, including the use of AI or ML algorithms for diagnostic purposes.
- Comparison with Traditional Diagnostic Approaches: Examination of whether the studies compared their diagnostic outcomes with traditional approaches to diagnose heart valve diseases, highlighting any improvements achieved through the use of AI or ML methods.
- Measurement of Diagnostic Accuracy and Error Rate Reduction: Assessment of whether the studies measured diagnostic accuracy and the reduction in error rates achieved by utilizing AI or ML techniques in diagnosing heart valve diseases.

For each of these quality criteria, a rating of ‘1’ indicated that the data available in the study clearly described the key characteristics of the item. A rating of ‘0’ was assigned when the data did not meet these criteria.

The systematic assessment of methodological quality and data extraction was performed on the included studies to facilitate a comprehensive analysis of their findings within the context of this systematic review.

3. Results

Overview of Included Studies
Three primary studies were identified and included in this systematic review, each exploring distinct aspects of valvular heart disease diagnosis utilizing advanced AI and machine learning methodologies.

Pathophysiological and Prognostic Insights in Aortic Stenosis (AS) Utilizing Biomarker - Driven Machine Learning
Article 01 delved into a cohort of 708 AS patients, leveraging a machine learning approach with multiple biomarkers. It unveiled significant associations between specific biomarkers such as NT - proBNP and adverse outcomes. Additionally, the study introduced a predictive model that emphasized the significance of interleukin-6 and fibroblast growth factor -23 in defining risk scores across various AS severity subgroups, employing AI - based predictive algorithms. (Table 01)

Enhanced Disease Prevalence Assessment and Identification Using AI - Driven Models
Article 02, analyzing a substantial cohort of 332, 919 patients via echocardiography reports and 484, 765 patients via ECGs, employed AI-driven models. This study not only assessed disease prevalence but also highlighted distinct characteristics among patients labeled positive for diseases. It conducted sensitivity analyses, showcasing varying AUROCs for different input features and achieving a notable AUROC of 0.92 with a 31.2% PPV at 90% sensitivity using severe - only disease labels, demonstrating the efficacy of AI-based predictive algorithms in disease identification. (Table 01)
Development of a Diagnostic Precision Algorithm for AS Identification and Prioritization

Article 03 innovated a Diagnostic Precision Algorithm using a dataset of 1, 147, 157 echocardiographic reports, aimed at identifying potentially missed severe AS diagnoses. The algorithm exhibited high accuracy in predicting the actual severe AS population proportion, indicating potential utility in minimizing missed diagnoses in clinical practice. This approach enables the prioritization of patients for secondary clinical review, offering a promising tool for AS identification and management. (Table 01)

### Table 1: Characteristics of Included Studies

<table>
<thead>
<tr>
<th>Study Name</th>
<th>Publication Year</th>
<th>Study Design</th>
<th>Sample Size</th>
<th>Patient Characteristics</th>
<th>Diagnostic Methods</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>01. Prime time for machine learning to predict clinical outcomes in valvular heart disease</td>
<td>2021</td>
<td>Cohort Study</td>
<td>708</td>
<td>Patients with Aortic Stenosis</td>
<td>Measurement of 49 key circulating plasma biomarkers; Network analyses; Use of TPOT for predictive model generation</td>
<td>The authors generated a classification predictive model by using model selection by a tree - based pipeline optimizer platform (TPOT). This model includes the most important biomarkers for risk of death or hospitalization for heart failure. It showed that interleukin - 6 (inflammation) and fibroblast growth factor - 23 (calcification) had the highest importance, which in other terms means that these are the variables with relatively the highest influence in the model. Also, the model could differentiate and classify patients in tertiles of risk (low, medium and high). Thereby, this model was able to define a risk score in subgroups of mild, moderate and severe AS.</td>
</tr>
<tr>
<td>02. ECG - based machine learning for predicting multiple structural heart conditions</td>
<td>2022</td>
<td>Cohort Study</td>
<td>484, 765</td>
<td>Adults linked to ECGs and electronic health records (1984 - 2021)</td>
<td>Machine learning models trained to predict presence/absence of 7 echocardiography - confirmed diseases</td>
<td>The study developed an ECG - based machine learning model, 'ECHOMmend', using age, sex, and ECG traces. The model showed a 0.91 area under the ROC curve and 42% positive predictive value at 90% sensitivity for a composite label of multiple heart conditions. Individual disease models had lower positive predictive values. The study suggests that this model could effectively identify a high - risk population for undiagnosed structural heart disease, outperforming single - disease models and improving practical utility for targeted echocardiography screening.</td>
</tr>
<tr>
<td>03. Artificial intelligence to assist physicians in identifying patients with severe aortic stenosis</td>
<td>2022</td>
<td>Diagnostic Precision Algorithm Development</td>
<td>1,147,157</td>
<td>Patients with suspected AS</td>
<td>Development of a Diagnostic Precision Algorithm using three standard Doppler indices (AVA, JV, and MPG); Compared model prediction with reported interpretation</td>
<td>The Diagnostic Precision Algorithm successfully predicted the actual severe AS population proportion with an average error of 2.1% points when LVEF was available and 2.2% points when LVEF was not available. It identified patients who may have incorrectly not received a severe AS diagnosis and prioritized these findings for secondary clinical review.</td>
</tr>
</tbody>
</table>

### Key Findings

All three studies underscored the potential of AI and machine learning in improving diagnostic accuracy and prognostic predictions for valvular heart diseases. Article 01 highlighted biomarker associations, Article 02 demonstrated robustness in identifying high - risk patients using ECG - based models, while Article 03 emphasized the potential for minimizing missed diagnoses in clinical practice through an AI - based Diagnostic Precision Algorithm. (Table 02)

### Table 2: Summary of Key Findings/Diagnostic Measures

<table>
<thead>
<tr>
<th>Article No.</th>
<th>Study Size</th>
<th>Diagnostic Methods</th>
<th>Key Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article 01</td>
<td>708 patients</td>
<td>Measurement of 49 biomarkers; Network analyses</td>
<td>- NT - proBNP strongly associated with risk of death - Predictive model with influential interleukin - 6 and fibroblast growth factor - 23</td>
</tr>
<tr>
<td>Article 02</td>
<td>332, 919 patients (echocardiography); 484, 765 patients (ECG)</td>
<td>Echocardiography and ECG assessment; Disease label identification</td>
<td>AUROCs ranging from 0.79 to 0.94 for different input features - rECHOMmend model achieved AUROC of 0.92 with 31.2% PPV at 90% sensitivity</td>
</tr>
</tbody>
</table>

**Volume 12 Issue 11, November 2023**

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY
| Article 03 | 1, 147, 157 echocardiographic reports | Diagnostic Precision Algorithm using Doppler indices (AVA, JV, and MPG) | - Diagnostic Precision Algorithm successfully predicted the actual severe AS population proportion with an average error of 2.1% points when LVEF was available and 2.2% points when LVEF was not available - Identified patients who may have missed a severe AS diagnosis, suggesting potential for minimizing missed diagnoses in clinical practice |

### Synthesis of Results
The reviewed studies collectively underscore the promising role of AI and machine learning in enhancing diagnostic precision and risk stratification for valvular heart diseases, providing valuable insights into pathophysiology, prognosis, and personalized risk assessment. These methodologies hold the potential to revolutionize disease detection and management in clinical settings.

### 4. Discussion

#### Overview of Systematic Review
This systematic review comprehensively explores recent advancements in the integration of artificial intelligence (AI) and machine learning within valvular heart disease diagnostics. Focused on the past five years, this review aims to assess the efficacy of predictive algorithms, AI-driven models, and technological innovations compared to traditional methods. Through an analysis of selected studies, it investigates improvements in diagnostic accuracy, risk prediction, and disease management across various valvular heart conditions. The overview highlights significant findings, limitations, future prospects, and conclusions drawn from the synthesis of these studies, aiming to provide valuable insights into the evolving landscape of AI in valvular heart disease diagnostics.

#### Predictive Algorithms for Severe AS Identification
The Diagnostic Precision Algorithm, devised through AI techniques, presents a novel approach to discerning severe AS. Its accuracy in predicting the proportions of severe AS patients highlights its potential for clinical prioritization. However, challenges involving variations in echocardiogram acquisition and the absence of robust clinical outcome data underline the need for further validation and seamless integration into clinical workflows.

#### Integration of AI in Cardiovascular Imaging
Studies exploring AI integration in cardiovascular imaging show promise in disease characterization and prognostic outcomes. The fusion of clinical and imaging data through machine learning models holds the potential for cost-effective and accurate diagnostic enhancements. Nevertheless, the need for broader cohort representation and robust validation is evident for wider clinical application.

#### Clarifying Ambiguous Diagnoses
AI algorithms, exemplified by the Diagnostic Precision Algorithm, offer significant strides in resolving ambiguous AS diagnoses, potentially mitigating misdiagnosis rates and healthcare costs. Challenges in echocardiographic accuracy and the necessity for comprehensive validation are paramount for seamless clinical implementation.

### Risk Prediction Leveraging Biomarkers
Insights from risk prediction models utilizing biomarkers showcase potential clinical applications. However, limitations in cohort inclusivity and external validation emphasize the importance of diverse dataset representation and robust validation procedures for broader clinical applicability.

### Advancements in Flow Dynamics Analysis
Innovations in flow dynamics analysis, including high-resolution imaging and computational modeling, hold promise for refining device design and patient-specific modeling. These advancements provide deeper insights into fluid-structure interactions and device behavior, paving the way for enhanced diagnostics and treatment planning.

### Clinical Utility of AI - Based Prediction Models
The eCHOMmend platform demonstrates high predictive accuracy but region-specific limitations. Addressing diversity in AI models and broader generalizability is pivotal for equitable applicability and wider clinical acceptance.

### 5. Limitations
The study focuses a lot on aortic stenosis because it's more common, but this might limit how well the findings apply to other heart valve diseases. The studies we looked at had different levels of checking and were often limited to specific groups or areas. We need more thorough checking to make sure the new AI diagnostic tools work well for different types of people and in different places. AI often uses echocardiograms, but these can change based on who does them and how good the images are. Making sure the AI is accurate despite these differences is really important for using it in hospitals. Some studies didn't have enough information about what happened to patients in the long run, so it's hard to know how well the new tools might work over time. There's a need to include people from different backgrounds in the AI models to make sure they work well for everyone, but this is still a challenge.

### 6. Future Prospects

a) **Refinement of Predictive Algorithms:** Future research should focus on refining predictive algorithms by incorporating diverse and comprehensive datasets, encompassing multiple valvular conditions to enhance accuracy and generalizability.

b) **Integration of Biomarkers and Imaging Data:** The convergence of biomarkers and imaging data within AI models presents a promising avenue for enhancing diagnostic precision and prognostic value across various valvular heart diseases.

c) **Validation and Clinical Implementation:** Broader validation efforts and clinical studies are imperative to

---

**Volume 12 Issue 11, November 2023**

[www.ijsr.net](http://www.ijsr.net)

**License under Creative Commons Attribution CC BY**

Paper ID: SR231122033950

DOI: [https://dx.doi.org/10.21275/SR231122033950](https://dx.doi.org/10.21275/SR231122033950)
seamlessly integrate AI - driven diagnostic tools into routine clinical practice, ensuring real - world efficacy and acceptance.

d) **Addressing Diversity in AI Models:** Efforts aimed at addressing ethno - racial diversity in AI models are essential to ensure equitable and accurate diagnostic outcomes across diverse patient populations.

e) **Longitudinal Outcome Assessment:** Future studies should encompass longer - term outcome assessments to evaluate the sustained efficacy and impact of AI - driven diagnostic tools on patient management and healthcare costs.

### 7. Conclusions

In conclusion, the reviewed studies underscore the significant strides made in utilizing AI and ML for diagnosing valvular heart disease, showcasing substantial advancements and acknowledging key challenges. The promising outcomes emphasize the need for continued research focusing on comprehensive validation, integration of diverse datasets, and improving echocardiographic accuracy to ensure clinically relevant and universally applicable diagnostic solutions.

While these advancements hold significant promise, critical challenges remain. Limitations centered around validation procedures, ensuring precise echocardiographic data, and the imperative of broader applicability across diverse populations need addressing. However, these challenges shouldn't deter progress. Instead, they underscore the necessity for ongoing refinement, robust validation, and integration of diverse datasets. This approach ensures the development of equitable, accurate, and clinically meaningful diagnostic outcomes in the management of valvular heart disease.

### References


